ABPI response to first innovation passport award

01 March 2021 Posted in News by Press Office

The Medicines and Healthcare Products Regulatory Agency (MHRA) has awarded the first 'innovation passport' under a new scheme to reduce the time for innovative medicines to get to market, known as the Innovative Licensing and Access Pathway (ILAP).

We look forward to seeing medicines coming through this scheme and getting to the people who need them as quickly as possible. Richard Torbett, Chief Executive, ABPI

In response, ABPI Chief Executive Richard Torbett said:

“It’s great to see the ILAP moving forward quickly with the award of the first innovation passport.

“Now the MHRA is a sovereign medicines regulator, this scheme is a really positive sign that the UK is serious about accelerating the approval of innovative new medicines, which is a win for patients, the NHS and industry.

“We look forward to seeing medicines coming through this scheme and getting to the people who need them as quickly as possible.”

TAGS
  • MHRA
  • ILAP

Last modified: 20 September 2023

Last reviewed: 20 September 2023

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.

Media enquiries

+44 (0) 20 7747 7147​​